Washington: The U.S. Food and Drug Administration has approved a new long-acting injectable medication for HIV prevention, marking a significant development in global HIV control strategies.
Unlike daily oral pre-exposure prophylaxis (PrEP), the injectable offers protection for several months per dose — a breakthrough that public health experts say could improve adherence, particularly among high-risk populations who face challenges maintaining daily medication regimens.
International agencies are now assessing affordability models and supply pathways to determine how quickly the innovation can be introduced in lower-income settings. In Pakistan, where localized HIV outbreaks have emerged in recent years, health professionals suggest that incorporating long-acting preventive options into targeted programs could enhance containment efforts — provided cost and procurement barriers are addressed.
